Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Integration of transcriptomics, proteomics and loss-of-function screening reveals WEE1 as a target for combination with dasatinib against proneural glioblastoma

Cancer Letters(2024)10.1016/j.canlet.2024.217265Source: DataRank Database

Integration of transcriptomics, proteomics and loss-of-function screening reveals WEE1 as a target for combination with dasatinib against proneural glioblastoma is a research paper published in Cancer Letters (2024). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

Linked data & code

geo doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)OA: hybridTopics (45)IDs (PubMed, PMC)Annotations (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (23)

Mona Göttmann,Maxwell P. Gold ORCID,Silja Schlue,Thomas Hielscher ORCID,Murat Iskar ORCID

Live enrichment

PubMed:39332586 PMC:PMC12768573

Deutsche Forschungsgemeinschaft

Grant: SFB 1389

Deutsche Forschungsgemeinschaft

Grant: 404521405

National Institutes of Health

Grant: U01CA253547

NIGMS NIH HHS

Grant: T32 GM087237

Deutsche Forschungsgemeinschaft

Grant: unidentified

unidentified

Foundation for the National Institutes of Health

hybridLicense: cc-by

publisherhttps://doi.org/10.1016/j.canlet.2024.217265

publisherhttps://api.elsevier.com/content/article/PII:S0304383524006608?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0304383524006608?httpAccept=text/plain

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC12768573/pdf/nihms-2119961.pdf

https://doi.org/10.2139/ssrn.4911234

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

Cell Line, TumorHumansGlioblastomaBrain NeoplasmsPyrazolesPyrimidinesPyrimidinonesCell Cycle ProteinsAntineoplastic Combined Chemotherapy ProtocolsProtein Kinase InhibitorsGene Expression ProfilingProteomicsGene Expression Regulation, NeoplasticDrug SynergismProtein-Tyrosine KinasesNeoplastic Stem CellsTranscriptomeDasatinib

Keywords

DasatinibWee1PhosphoproteomicsComputational IntegrationLoss-of-function Shrna ScreenProteomicsCell Cycle ProteinsPyrimidinonesArticleCell Line, TumorAntineoplastic Combined Chemotherapy ProtocolsHumans1306 Cancer ResearchProtein Kinase InhibitorsBrain NeoplasmsGene Expression ProfilingDrug SynergismProtein-Tyrosine KinasesGene Expression Regulation, NeoplasticPyrimidinesNeoplastic Stem CellsPyrazoles2730 OncologyGlioblastomaTranscriptome

Integration of transcriptomics, proteomics and loss-of-function screening reveals WEE1 as a target for combination with dasatinib against proneural glioblastoma

FAIR Checklist

Authors (23)

Funding (6 grants)

Open Access

Topics

Annotations (Europe PMC)